As such, the authors simultaneously targeted both c-Met/TrkA-B (using altiratinib) pathways along with CDK4/6 (using abemaciclib) and observed a synergistic anti-tumor response with enhanced apoptosis after combination therapy. The gene discussed is MET; the disease is neoplasm.